2019 Edogawa NICHE Prize Awarded to Dr. Steven Rosenberg for His Pioneering Feat in Tackling Cancer with Immunotherapy
15.8.2019 09:00:00 EEST | Business Wire | Press release
The Edogawa NICHE Committee today announced that the 2019-Edogawa NICHE Prize (www.edogawanicheprize.org) has been awarded to Dr. Steven A. Rosenberg, for his pioneering work in developing effective adoptive immunotherapies and genetically modified T cells which has heralded the birth of a new chapter in the fight against cancer. Dr. Rosenberg’s accomplishment has significantly contributed to the development of several immune system-based drugs and clinically effective immunotherapies including the CAR-T cell therapy.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190814005237/en/
Dr. Steven A. Rosenberg, 2019 Edogawa NICHE Prize Awardee (Photo: Business Wire)
Dr. Rosenberg is an epitome of significance of inter-disciplinary interaction in developing clinical solutions, who after his Medical degree at Johns Hopkins University, obtained doctorate in Biophysics. Now leads a strong interdisciplinary team devoted to find novel solutions to cancer, as the Chief, Surgery Branch at the National Cancer Institute (NCI), MD, USA and as Professor of Surgery at the Uniformed Services University of Health Sciences and the George Washington University School of Medicine and Health Science.
Instead of two or more specialists’ interaction, making the inter-disciplinary interaction meaningful, we found one passionate scholar in Dr. Rosenberg, walking through the portals of different domains of science by himself, opening a new path to solve an age-old problem is considered worth that this award be bestowed on him, said Dr. Masahiro Katoh, Chairperson, Edogawa NICHE Committee.
In the 2019 Edogawa NICHE Prize Award ceremony at University of Toronto, Canada, Prof Gary Levy, Chair, Awards Committee & Founding Director, CIHR, Transplant program, will honour Dr. Rosenberg with a medal & plaque, whose acceptance speech will be videocasted in NCRM NICHE 2019 in Tokyo, Japan, followed by 2019 Joyce & James Till Travel Grant recipient, PV Sudharsan, a 2012-FCQ elite sharing how FCQ helped in his career (www.j2t2grant.org), and a presentation on Training Program in Regenerative Medicine (www.regenmedcanada.com).
Instituted in 2018, by Jinseisha trust, which owns Edogawa Hospital, Tokyo and Nichi-In Centre for Regenerative Medicine (NCRM), the Edogawa NICHE Prize honours scientists or clinicians whose contributions lead to the development of prevention, diagnosis or treatment of any disease, through an inter-disciplinary interaction. Scholars who attain top scores in the Fujio Cup Quiz since 2006, a part of NCRM NICHE, (www.ncrmniche.org) and gain FCQ Elite status, have a priority to nominate the awardees, which is unique to this prize.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190814005237/en/
Contact information
Queries to:
GN Corporation Co. Ltd.
Samuel Jk Abraham
info@gncorporation.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Compass Pathways Announces Six-Month Data from Second Phase 3 Trial Confirming Rapid and Durable Profile7.7.2026 13:30:00 EEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced today the 26-week results (Part B) from its second ongoing Phase 3 COMP006 trial of COMP360, a synthetic, proprietary formulation of psilocybin, for treatment-resistant depression (TRD) which confirm COMP360’s rapid onset and durable profile. The 26-week findings in nearly 600 patients build on previously reported results from the first Phase 3 trial, COMP005, which demonstrated rapid onset and durable response to at least 6 months, with a generally well-tolerated and safe profile in people living with TRD. The COMP360 Phase 3 program participants represent a highly chronic TRD population. In COMP006, participants had current depressive episodes lasting on average over three years and an average of more than six lifetime depressive episodes. Within the context of this severe population, 39% of participants in the 25 mg arm achieved a clinically m
Private Department of Sheikh Mohammed bin Khalid Al Nahyan Invests in MidOcean Energy and Forms Strategic Partnership with EIG7.7.2026 13:16:00 EEST | Press release
The Private Department of Sheikh Mohammed bin Khalid Al Nahyan (the “Private Department”) has today committed to invest $1.13bn in MidOcean Energy (“MidOcean” or the “Company”), a liquefied natural gas (LNG) company formed and managed by EIG. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260707259928/en/ In parallel with the investment, the Private Department and EIG have established a strategic partnership focused on capital aggregation, investment origination, and the development of institutional investment opportunities across the United Arab Emirates and selected regional markets. The Investment in MidOcean represents the Private Department’s entry into the global LNG sector and marks the launch of a broader strategic relationship with EIG, a global energy and infrastructure investment firm. Through this partnership, the parties intend to collaborate on future investment opportunities across the energy and related infra
Infobip Research Reveals Businesses Scaling AI-Powered Defenses to Counter Surge in Automated Fraud7.7.2026 12:55:00 EEST | Press release
New research from global AI-first cloud communications platform Infobip reveals a growing surge in AI-powered fraud and enterprise defenses. Analyzing billions of interactions globally, Infobip’s 2026 Fraud & Security Report highlights a year of dramatic contrasts. There have been record volumes of blocked fraudulent traffic alongside the rapid scaling of intelligent, AI-powered defenses. The report reveals that while fraudsters are using AI to scale and personalize harmful messaging, leading to a 77% increase in detected threats, businesses are responding in kind. Adoption of AI-powered fraud detection grew by 71% year-on-year, while pattern-based detection increased by 105%, underscoring a shift toward adaptive security. The report demonstrates the impact of AI-first security. Leading UK-based clothing brand NEXT is leveraging Infobip Signals, an AI and machine learning-powered solution designed to combat artificially inflated traffic, helping protect customers against fraud. Raz Raz
Santander Financial Crime Transformation Leader Joins ThetaRay to Drive Enterprise AI Adoption7.7.2026 11:00:00 EEST | Press release
ThetaRay, a leader in AI infrastructure for financial crime compliance, today announced the appointment of Luis Pinedo as Chief Strategic Customers Officer. Previously Pinedo was Group VP of Compliance at Santander Bank, where during his 16-year tenure, he led global Financial Crime Compliance (FCC) transformation initiatives across operating models, processes, and technology platforms. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260707359150/en/ Luis Pinedo joins ThetaRay as Chief Strategic Customers Officer. In his new role, Pinedo will bring key perspectives from tier-one banking operational challenges to ThetaRay’s product development and design. He will lead strategic customer engagement as well as product strategy across ThetaRay’s entire compliance platform, including Transaction Monitoring, Screening, Customer Risk Assessment, and Agentic Investigations. The appointment comes at a critical time in the RegTech indu
Robbyant Unveils LingBot-Depth 2.0 and LingBot-Vision to Redefine Robotic Spatial Perception7.7.2026 10:54:00 EEST | Press release
Robbyant, an embodied AI company within Ant Group, today announced the launch of LingBot-Depth 2.0, a next-generation spatial perception model, alongside its foundational visual model, LingBot-Vision. This release marks a significant leap in robotic spatial perception, empowering robots to accurately understand and navigate the physical world. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706806935/en/ LingBot-Depth 2.0 reconstructs complete and planar 3D structures in challenging scenarios involving mirrors and glass From "Seeing" to "Seeing Accurately" Building upon the success of LingBot-Depth, which pioneered the Masked Depth Modeling (MDM) technique to resolve depth sensing challenges for transparent and reflective surfaces, LingBot-Depth 2.0 represents a massive scale-up in training data and performance. Trained on 150 million samples, the new model achieves top rankings in 12 out of 16 depth completion benchmarks.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom